Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by VICTOR PRIETO and ALEXANDER LAZAR.
VICTOR PRIETO
Connection Strength
2.130
ALEXANDER LAZAR
  1. Index report of cutaneous angiosarcomas with strong positivity for tyrosinase mimicking melanoma with further evaluation of melanocytic markers in a large angiosarcoma series. J Cutan Pathol. 2017 Aug; 44(8):692-697.
    View in: PubMed
    Score: 0.149
  2. Trichilemmomas show loss of PTEN in Cowden syndrome but only rarely in sporadic tumors. J Cutan Pathol. 2012 May; 39(5):493-9.
    View in: PubMed
    Score: 0.104
  3. Sarcoma metastases to the skin: a clinicopathologic study of 65 patients. Cancer. 2012 Jun 01; 118(11):2900-4.
    View in: PubMed
    Score: 0.101
  4. Epidermal growth factor receptor (EGFR) expression in periocular and extraocular sebaceous carcinoma. J Cutan Pathol. 2010 Feb; 37(2):231-6.
    View in: PubMed
    Score: 0.086
  5. Cutaneous and subcutaneous metastases of gastrointestinal stromal tumors: a series of 5 cases with molecular analysis. Am J Dermatopathol. 2009 May; 31(3):297-300.
    View in: PubMed
    Score: 0.085
  6. The usefulness of p63 detection for differentiating primary from metastatic skin adenocarcinomas. J Cutan Pathol. 2008 Sep; 35(9):880-1.
    View in: PubMed
    Score: 0.081
  7. Metastasizing adenocarcinoma and multiple neoplastic proliferations arising in a nevus sebaceus. Am J Dermatopathol. 2007 Oct; 29(5):462-6.
    View in: PubMed
    Score: 0.076
  8. A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ. Am J Surg Pathol. 2007 Jul; 31(7):1130-6.
    View in: PubMed
    Score: 0.075
  9. Use of p63 expression in distinguishing primary and metastatic cutaneous adnexal neoplasms from metastatic adenocarcinoma to skin. J Cutan Pathol. 2007 Jun; 34(6):474-80.
    View in: PubMed
    Score: 0.074
  10. Merkel cell tumor in a trichilemmal cyst: collision or association? Am J Dermatopathol. 2007 Apr; 29(2):180-3.
    View in: PubMed
    Score: 0.074
  11. Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients. Am J Dermatopathol. 2007 Feb; 29(1):62-7.
    View in: PubMed
    Score: 0.073
  12. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res. 2006 Nov 15; 12(22):6709-15.
    View in: PubMed
    Score: 0.072
  13. Telomerase reverse transcriptase immunohistochemical expression is sensitive but not specific for TERT gene amplification in acral melanoma. J Cutan Pathol. 2023 Sep; 50(9):845-851.
    View in: PubMed
    Score: 0.057
  14. Annular plaques: An unusual manifestation of graft-versus-host disease. Dermatol Online J. 2012 Jun 15; 18(6):4.
    View in: PubMed
    Score: 0.053
  15. Expression of TRPS1 in phyllodes tumor and sarcoma of the breast. Hum Pathol. 2022 03; 121:73-80.
    View in: PubMed
    Score: 0.051
  16. Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee. J Cutan Pathol. 2022 Mar; 49(3):231-245.
    View in: PubMed
    Score: 0.050
  17. Telomerase Reverse Transcriptase Protein Expression Is More Frequent in Acral Lentiginous Melanoma Than in Other Types of Cutaneous Melanoma. Arch Pathol Lab Med. 2021 07 01; 145(7):842-850.
    View in: PubMed
    Score: 0.049
  18. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
    View in: PubMed
    Score: 0.043
  19. B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density. Clin Cancer Res. 2019 06 01; 25(11):3455-3467.
    View in: PubMed
    Score: 0.042
  20. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
    View in: PubMed
    Score: 0.041
  21. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.041
  22. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.041
  23. Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. J Cutan Pathol. 2018 Aug; 45(8):563-580.
    View in: PubMed
    Score: 0.040
  24. Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. J Am Acad Dermatol. 2019 Jan; 80(1):189-207.e11.
    View in: PubMed
    Score: 0.040
  25. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017 03 01; 9(379).
    View in: PubMed
    Score: 0.037
  26. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016 08; 6(8):827-37.
    View in: PubMed
    Score: 0.035
  27. Metastatic atypical fibroxanthoma: a series of 11 cases including with minimal and no subcutaneous involvement. Am J Dermatopathol. 2015 Jun; 37(6):455-61.
    View in: PubMed
    Score: 0.032
  28. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.
    View in: PubMed
    Score: 0.032
  29. Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.
    View in: PubMed
    Score: 0.032
  30. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.
    View in: PubMed
    Score: 0.031
  31. Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014 Nov 01; 20(21):5537-46.
    View in: PubMed
    Score: 0.030
  32. Cutaneous digital papillary adenocarcinoma: a clinicopathologic study of 31 cases of a rare neoplasm with new observations. Am J Surg Pathol. 2012 Dec; 36(12):1883-91.
    View in: PubMed
    Score: 0.027
  33. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res. 2012 Feb 15; 18(4):1120-8.
    View in: PubMed
    Score: 0.026
  34. Dermatofibrosarcoma protuberans with unusual sarcomatous transformation: a series of 4 cases with molecular confirmation. Am J Dermatopathol. 2011 Jun; 33(4):354-60.
    View in: PubMed
    Score: 0.025
  35. COL1A1:PDGFB chimeric transcripts are not present in indeterminate fibrohistiocytic lesions of the skin. Am J Dermatopathol. 2010 Apr; 32(2):149-53.
    View in: PubMed
    Score: 0.023
  36. Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases. Mod Pathol. 2010 Apr; 23(4):567-73.
    View in: PubMed
    Score: 0.022
  37. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res. 2009 Dec 15; 15(24):7538-7546.
    View in: PubMed
    Score: 0.022
  38. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol. 2009 Nov; 22(11):1446-56.
    View in: PubMed
    Score: 0.022
  39. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008 Oct 21; 99(8):1265-8.
    View in: PubMed
    Score: 0.020
  40. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. Mod Pathol. 2008 Sep; 21(9):1121-9.
    View in: PubMed
    Score: 0.020
  41. Cellular blue nevi of the eyelid: A possible diagnostic pitfall. J Am Acad Dermatol. 2008 Feb; 58(2):257-60.
    View in: PubMed
    Score: 0.019
  42. Metastatic basal cell carcinoma exhibits reduced actin expression. Mod Pathol. 2008 May; 21(5):540-3.
    View in: PubMed
    Score: 0.019
  43. Dermatofibrosarcoma protuberans and giant cell fibroblastoma exhibit CD99 positivity. J Cutan Pathol. 2008 Jul; 35(7):647-50.
    View in: PubMed
    Score: 0.019
  44. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays. Hum Pathol. 2008 Feb; 39(2):184-93.
    View in: PubMed
    Score: 0.019
  45. Renal cell carcinoma marker (RCC-Ma) is specific for cutaneous metastasis of renal cell carcinoma. J Cutan Pathol. 2007 May; 34(5):381-5.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.